"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...